Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection.
<h4>Background</h4>Interferon and ribavirin therapy for chronic hepatitis C virus (HCV) infection yields sustained virological response (SVR) rates of 50-80%. Several factors such as non-1 genotype, beneficial IL28B genetic variants, low baseline IP-10, and the functionality of HCV-speci...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/c0896e787ce34d95bdd38ea0428e8b40 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:c0896e787ce34d95bdd38ea0428e8b40 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:c0896e787ce34d95bdd38ea0428e8b402021-11-18T07:56:44ZImpact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection.1932-620310.1371/journal.pone.0056991https://doaj.org/article/c0896e787ce34d95bdd38ea0428e8b402013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23437290/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Interferon and ribavirin therapy for chronic hepatitis C virus (HCV) infection yields sustained virological response (SVR) rates of 50-80%. Several factors such as non-1 genotype, beneficial IL28B genetic variants, low baseline IP-10, and the functionality of HCV-specific T cells predict SVR. With the pending introduction of new therapies for HCV entailing very rapid clearance of plasma HCV RNA, the importance of baseline biomarkers likely will increase in order to tailor therapy. CD26 (DPPIV) truncates the chemokine IP-10 into a shorter antagonistic form, and this truncation of IP-10 has been suggested to influence treatment outcome in patients with chronic HCV infection patients. In addition, previous reports have shown CD26 to be a co-stimulator for T cells. The aim of the present study was to assess the utility of CD26 as a biomarker for treatment outcome in chronic hepatitis C and to define its association with HCV-specific T cells.<h4>Methods</h4>Baseline plasma from 153 genotype 1 and 58 genotype 2/3 infected patients enrolled in an international multicenter phase III trial (DITTO-HCV) and 36 genotype 1 infected patients participating in a Swedish trial (TTG1) were evaluated regarding baseline soluble CD26 (sCD26) and the functionality of HCV-specific CD8(+) T cells.<h4>Results</h4>Genotype 1 infected patients achieving SVR in the DITTO (P = 0.002) and the TTG1 (P = 0.02) studies had lower pretreatment sCD26 concentrations compared with non-SVR patients. Sixty-five percent of patients with sCD26 concentrations below 600 ng/mL achieved SVR compared with 39% of the patients with sCD26 exceeding 600 ng/mL (P = 0.01). Patients with sCD26 concentrations below 600 ng/mL had significantly higher frequencies of HCV-specific CD8(+) T cells (P = 0.02).<h4>Conclusions</h4>Low baseline systemic concentrations of sCD26 predict favorable treatment outcome in chronic HCV infection and may be associated with higher blood counts of HCV-specific CD8(+) T cells.Jonas SöderholmJesper WaldenströmGalia AskariehMassimo PilliPierre-Yves BochudFrancesco NegroJean-Michel PawlotskyStefan ZeuzemCarlo FerrariCarlo FerrariGunnar NorkransRune WejstålJohan WestinAvidan U NeumannBart L HaagmansMagnus LindhGabriele MissaleKristoffer HellstrandMartin LaggingPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 2, p e56991 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Jonas Söderholm Jesper Waldenström Galia Askarieh Massimo Pilli Pierre-Yves Bochud Francesco Negro Jean-Michel Pawlotsky Stefan Zeuzem Carlo Ferrari Carlo Ferrari Gunnar Norkrans Rune Wejstål Johan Westin Avidan U Neumann Bart L Haagmans Magnus Lindh Gabriele Missale Kristoffer Hellstrand Martin Lagging Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection. |
| description |
<h4>Background</h4>Interferon and ribavirin therapy for chronic hepatitis C virus (HCV) infection yields sustained virological response (SVR) rates of 50-80%. Several factors such as non-1 genotype, beneficial IL28B genetic variants, low baseline IP-10, and the functionality of HCV-specific T cells predict SVR. With the pending introduction of new therapies for HCV entailing very rapid clearance of plasma HCV RNA, the importance of baseline biomarkers likely will increase in order to tailor therapy. CD26 (DPPIV) truncates the chemokine IP-10 into a shorter antagonistic form, and this truncation of IP-10 has been suggested to influence treatment outcome in patients with chronic HCV infection patients. In addition, previous reports have shown CD26 to be a co-stimulator for T cells. The aim of the present study was to assess the utility of CD26 as a biomarker for treatment outcome in chronic hepatitis C and to define its association with HCV-specific T cells.<h4>Methods</h4>Baseline plasma from 153 genotype 1 and 58 genotype 2/3 infected patients enrolled in an international multicenter phase III trial (DITTO-HCV) and 36 genotype 1 infected patients participating in a Swedish trial (TTG1) were evaluated regarding baseline soluble CD26 (sCD26) and the functionality of HCV-specific CD8(+) T cells.<h4>Results</h4>Genotype 1 infected patients achieving SVR in the DITTO (P = 0.002) and the TTG1 (P = 0.02) studies had lower pretreatment sCD26 concentrations compared with non-SVR patients. Sixty-five percent of patients with sCD26 concentrations below 600 ng/mL achieved SVR compared with 39% of the patients with sCD26 exceeding 600 ng/mL (P = 0.01). Patients with sCD26 concentrations below 600 ng/mL had significantly higher frequencies of HCV-specific CD8(+) T cells (P = 0.02).<h4>Conclusions</h4>Low baseline systemic concentrations of sCD26 predict favorable treatment outcome in chronic HCV infection and may be associated with higher blood counts of HCV-specific CD8(+) T cells. |
| format |
article |
| author |
Jonas Söderholm Jesper Waldenström Galia Askarieh Massimo Pilli Pierre-Yves Bochud Francesco Negro Jean-Michel Pawlotsky Stefan Zeuzem Carlo Ferrari Carlo Ferrari Gunnar Norkrans Rune Wejstål Johan Westin Avidan U Neumann Bart L Haagmans Magnus Lindh Gabriele Missale Kristoffer Hellstrand Martin Lagging |
| author_facet |
Jonas Söderholm Jesper Waldenström Galia Askarieh Massimo Pilli Pierre-Yves Bochud Francesco Negro Jean-Michel Pawlotsky Stefan Zeuzem Carlo Ferrari Carlo Ferrari Gunnar Norkrans Rune Wejstål Johan Westin Avidan U Neumann Bart L Haagmans Magnus Lindh Gabriele Missale Kristoffer Hellstrand Martin Lagging |
| author_sort |
Jonas Söderholm |
| title |
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection. |
| title_short |
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection. |
| title_full |
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection. |
| title_fullStr |
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection. |
| title_full_unstemmed |
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection. |
| title_sort |
impact of soluble cd26 on treatment outcome and hepatitis c virus-specific t cells in chronic hepatitis c virus genotype 1 infection. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/c0896e787ce34d95bdd38ea0428e8b40 |
| work_keys_str_mv |
AT jonassoderholm impactofsolublecd26ontreatmentoutcomeandhepatitiscvirusspecifictcellsinchronichepatitiscvirusgenotype1infection AT jesperwaldenstrom impactofsolublecd26ontreatmentoutcomeandhepatitiscvirusspecifictcellsinchronichepatitiscvirusgenotype1infection AT galiaaskarieh impactofsolublecd26ontreatmentoutcomeandhepatitiscvirusspecifictcellsinchronichepatitiscvirusgenotype1infection AT massimopilli impactofsolublecd26ontreatmentoutcomeandhepatitiscvirusspecifictcellsinchronichepatitiscvirusgenotype1infection AT pierreyvesbochud impactofsolublecd26ontreatmentoutcomeandhepatitiscvirusspecifictcellsinchronichepatitiscvirusgenotype1infection AT francesconegro impactofsolublecd26ontreatmentoutcomeandhepatitiscvirusspecifictcellsinchronichepatitiscvirusgenotype1infection AT jeanmichelpawlotsky impactofsolublecd26ontreatmentoutcomeandhepatitiscvirusspecifictcellsinchronichepatitiscvirusgenotype1infection AT stefanzeuzem impactofsolublecd26ontreatmentoutcomeandhepatitiscvirusspecifictcellsinchronichepatitiscvirusgenotype1infection AT carloferrari impactofsolublecd26ontreatmentoutcomeandhepatitiscvirusspecifictcellsinchronichepatitiscvirusgenotype1infection AT carloferrari impactofsolublecd26ontreatmentoutcomeandhepatitiscvirusspecifictcellsinchronichepatitiscvirusgenotype1infection AT gunnarnorkrans impactofsolublecd26ontreatmentoutcomeandhepatitiscvirusspecifictcellsinchronichepatitiscvirusgenotype1infection AT runewejstal impactofsolublecd26ontreatmentoutcomeandhepatitiscvirusspecifictcellsinchronichepatitiscvirusgenotype1infection AT johanwestin impactofsolublecd26ontreatmentoutcomeandhepatitiscvirusspecifictcellsinchronichepatitiscvirusgenotype1infection AT avidanuneumann impactofsolublecd26ontreatmentoutcomeandhepatitiscvirusspecifictcellsinchronichepatitiscvirusgenotype1infection AT bartlhaagmans impactofsolublecd26ontreatmentoutcomeandhepatitiscvirusspecifictcellsinchronichepatitiscvirusgenotype1infection AT magnuslindh impactofsolublecd26ontreatmentoutcomeandhepatitiscvirusspecifictcellsinchronichepatitiscvirusgenotype1infection AT gabrielemissale impactofsolublecd26ontreatmentoutcomeandhepatitiscvirusspecifictcellsinchronichepatitiscvirusgenotype1infection AT kristofferhellstrand impactofsolublecd26ontreatmentoutcomeandhepatitiscvirusspecifictcellsinchronichepatitiscvirusgenotype1infection AT martinlagging impactofsolublecd26ontreatmentoutcomeandhepatitiscvirusspecifictcellsinchronichepatitiscvirusgenotype1infection |
| _version_ |
1718422754775007232 |